PRINCETON, N.J., Feb. 28, 2018 /PRNewswire/ -- MAIA Pharmaceuticals, Inc., a Princeton, NJbased specialty pharmaceutical company, announces the Tentative Approval of its Sincalide for Injection NDA by the U.S. Food and Drug Administration (FDA).
As of 2013, there were over 648,000 patients1 where KINEVAC®2 was
MAIA's Sincalide for Injection is a new and innovative formulation of sincalide that addresses the recurrent shortages of KINEVAC® as well as KINEVAC®'s shelf-life issues. Recognizing the shortages of KINEVAC and the unmet medical need, the FDA granted "Priority Review" to MAIA's NDA.
"We are pleased to have received this Tentative Approval for Sincalide for Injection. This is a huge step towards getting patients access to a drug that has been plagued by recurrent supply issues for many years forcing practitioners to rely on less than desirable alternatives to address their need which include using preparations from compounding pharmacies or alternate therapies, which are not approved by the FDA. We hope to restore a consistent supply of a stable product, for which there is a clear unmet and public health need," said Dr. Srikanth Sundaram, President and CSO of MAIA.
"With the FDA's tentative approval of MAIA's NDA, the only issue precluding MAIA from supplying sincalide to heath care practitioners and patients who desperately need it is the ongoing patent litigation with Bracco Diagnostics Inc., which we are confident will be resolved in MAIA's favor," said Bikram Malik, Operations, MAIA.
"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. The tentative approval will be eligible for conversion to a final approval subject to the resolution of the current patent litigation between MAIA and Bracco Diagnostics Inc.
IndicationsSincalide for Injection is indicated in adults to:
About MAIA Pharmaceuticals, Inc.MAIA is a Princeton, NJ based specialty pharmaceutical company focused on developing and bringing to market injectable products where there are unaddressed patient and/or practitioner needs.
1 Based upon Bracco Diagnostics public statements2 KINEVAC® is a registered trademark of Bracco Diagnostics Inc.
Contact: Bikram Malik, 1-973-296-8084, firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/maia-pharmaceuticals-announces-the-tentative-approval-by-the-fda-of-its-nda-for-sincalide-for-injection-300605478.html
SOURCE MAIA Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All